Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
“I feel so fortunate that I’ve been given a second chance," says Schuman, who was diagnosed with melanoma in 2018.
It’s possible to identify these individuals in advance, helping them to focus on clinical trials of more effective treatments.
“This may be the solution to many problems,” says researcher Rizwan Haq, MD, PhD.
The combination of chemoimmunotherapy with a targeted drug represents a step toward a new standard of care for people with CLL.
New research asks if an alternative dosing schedule can produce the same effects with fewer side effects.
The method identifies which targeted therapies, inadequate on their own, can be paired up to kill non-responsive cancers.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
The study used two FDA-approved drugs to the pre-leukemic cells while leaving healthy stem cells alone.
When Derrick tells the story of his journey with melanoma, the overwhelming theme is gratitude—for doctors, researchers and loved ones.
Unbiased approach reveals why so many breast cancer drug trials have failed — and how to restore promising drugs’ cancer-killing potential...
“We’re doing well, but we can do even better by personalizing therapies,” said Roy Herbst, MD, PhD, of the Yale Cancer Center.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.